Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating depression and preparation method thereof

A composition and depression technology, applied in the field of medicine, can solve the problems of material waste, powder layer, flying, and increased product cost.

Inactive Publication Date: 2014-02-12
BEIJING D VENTUREPHARM TECH DEV
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Direct compression has high requirements for pharmaceutical excipients and equipment, and it is easy to cause waste of materials and flying powder layers, which virtually increases the cost of the product during the preparation process

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating depression and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Escitalopram Oxalate 10.2% talcum powder 5.5% microcrystalline cellulose 79.6% Croscarmellose Sodium 4.0% Magnesium stearate 0.7%

[0021] Preparation process: First, mix escitalopram oxalate and talcum powder evenly, then add the prescribed amount of microcrystalline cellulose, mix evenly, and then dry press into large tablets to granulate. After adding croscarmellose sodium and magnesium stearate and mixing evenly, the tablet was pressed to measure the tablet weight and hardness.

Embodiment 2

[0023] Escitalopram Oxalate 10.2% silica 6% microcrystalline cellulose 77.8% Croscarmellose Sodium 5.0% Magnesium stearate 1.0%

[0024] Preparation process: First, mix escitalopram oxalate and silicon dioxide evenly, then add the prescribed amount of microcrystalline cellulose, mix evenly, and then dry press into large tablets to granulate. After adding croscarmellose sodium and magnesium stearate and mixing evenly, the tablet was pressed to measure the tablet weight and hardness.

Embodiment 3

[0026] Escitalopram Oxalate 10.2% talcum powder 5.5% microcrystalline cellulose 65.3% Mannitol 12.0% Croscarmellose Sodium 6.0% Magnesium stearate 1.0%

[0027] Preparation process: First, mix escitalopram oxalate and talcum powder evenly, then add the prescribed amount of microcrystalline cellulose and mannitol, mix evenly, and then dry press into large tablets to granulate. After adding croscarmellose sodium and magnesium stearate and mixing evenly, the tablet was pressed to measure the tablet weight and hardness.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicine, and particularly relates to a pharmaceutical composition for treating depression and a preparation method thereof. The preparation is an oral solid preparation and contains an active component with general formula of (S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile oxalate (Escitalopram oxalate), microcrystalline cellulose and a compressible excipient; and the preparation has the characteristic of quick dissolution and is of great significance to the treatment of depression.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to an oral solid preparation for treating depression. The active ingredient of the preparation is escitalopram oxalate, which is named by INN as escitalopram oxalate, and its common name is (S)- 1-[3-(Dimethylamino)propyl-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile oxalate. Background technique [0002] With the acceleration of the pace of life, people's mental health has received more and more attention. Escitalopram oxalate is the S-isomer of racemic citalopram, and its structural formula is: [0003] [0004] is a selective oral serotonin reuptake inhibitor (SSRI) for the treatment of major depressive disorder and generalized anxiety. [0005] Escitalopram oxalate is a product jointly developed by Forest Laboratories of the United States and Lundbeck Pharmaceutical Factory of Denmark. The oral solid tablet is now imported. The domestic product is produced by Lundbeck Ph...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/343A61P25/24
Inventor 贾煜娇孟旻郭夏
Owner BEIJING D VENTUREPHARM TECH DEV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com